A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

NCT05993234 · clinicaltrials.gov ↗

RECRUITING

Status

257

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Advanced Gastric Cancer
HER2-positive Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Trastuzumab deruxtecan

Sponsor

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company